HCPCS code J2210 – Methylergonovine maleate injection

Key takeaways

HCPCS code J2210 covers methylergonovine maleate injection at up to 0.2 mg per billing unit, and the oral tablet is not covered.

Each 1 mL vial contains 0.2 mg, so a single-vial dose equals exactly one billable unit. Doses spanning multiple vials are billed in proportional units.

Medicare Part B has required JZ on fully used single-dose vials since July 1, 2023. Discarded drug goes on its own line with JW, required since 2017, and other payers vary.

Pabau’s claims management software tracks J-code units, modifier rules, and NDC fields in one workflow, reducing denials before claims leave the practice.

HCPCS code J2210: Official descriptor and drug overview

HCPCS code J2210 is the CMS-assigned Level II code for “injection, methylergonovine maleate, up to 0.2 mg.” The descriptor defines a single billing unit as up to 0.2 mg of the drug administered by injection. Oral formulations of methylergonovine are excluded from J2210 entirely.

Methylergonovine maleate is a semi-synthetic ergot alkaloid used as a uterotonic. It produces sustained contraction of the uterus. The drug is sold under the brand name Methergine and also appears in coding literature as methylergometrine.

Clinical use and covered indications

Methylergonovine maleate is indicated for routine management after delivery of the placenta, postpartum atony and hemorrhage, and subinvolution. These are the FDA-approved indications that support medical necessity when billing J2210.

Billers should know one clinical boundary. The drug is contraindicated in patients with hypertension, per FDA DailyMed prescribing information. A documented blood pressure check before administration strengthens a J2210 claim and shows appropriate patient selection.

• Postpartum hemorrhage (PPH) due to uterine atony: Primary indication and the most common billing context
• Uterine subinvolution: Failure of the uterus to return to normal size postpartum
• Postpartum bleeding: Documented hemorrhage requiring uterotonic intervention
• Oral tablet formulation: Not covered by J2210, because the descriptor specifies the injection route only

Pair J2210 with a covered diagnosis, which you can confirm in our ICD-10-CM lookup for coders. The O72.x code family covers postpartum hemorrhage. O72.1 (other immediate postpartum hemorrhage) and O72.2 (delayed and secondary postpartum hemorrhage) are the most commonly linked diagnoses. Without a covered diagnosis code, payers treating J2210 as elective will deny it on medical necessity grounds.

Dosage, vial size, and unit calculation

The standard methylergonovine maleate vial is 1 mL containing 0.2 mg. Because J2210 is billed “up to 0.2 mg” per unit, one vial equals one billable unit. That sounds simple, but it causes steady over-billing when the dose is recorded in micrograms rather than milligrams.

Common calculation error: A nurse documents “200 mcg IM given.” The biller reads “200” and bills 200 units. The correct reading is 200 micrograms = 0.2 mg = 1 unit. Always confirm whether the clinical note records the dose in mg or mcg before entering the unit count.

How to bill J2210: Claim structure and CPT administration codes

J2210 is a drug code, not a procedure code. It always appears on the claim alongside a CPT administration code that describes how the injection was given. Submitting J2210 without an administration code is a structural claim error.

The administration code follows the route. Methergine’s standard route is intramuscular, so CPT 96372 is the usual companion code. It covers a therapeutic subcutaneous or intramuscular injection. For an IV push, which is not routine, bill CPT 96374 for the single or initial push. Use CPT 96375 for each additional sequential IV push of a new drug.

On the CMS-1500 form, J2210 and its modifiers go in Box 24D, and the units go in Box 24G. The administration CPT code sits on its own claim line. On a UB-04 for hospital outpatient settings, revenue code 0636 (drugs requiring specific identification) goes in Form Locator 42. The HCPCS code and its modifiers go in Form Locator 44.

Required modifiers when billing J2210

CMS has required the JW modifier for discarded drug from single-dose containers since January 1, 2017. The JZ modifier, which reports zero waste, became required for Medicare Part B on July 1, 2023. Since October 1, 2023, Medicare can return claims missing the right modifier as unprocessable.

Every Medicare Part B claim line for a single-dose vial must carry JZ (no waste) or JW (on the waste line). The administered-dose line has no modifier when waste is reported. JW and JZ never appear together on one claim. Other payers set their own rules, so check each commercial and Medicaid policy.

Put together, the drug lines and the administration line look like this for the three doses in the unit table above.

NDC reporting requirements for J2210 claims

Medicaid requires the National Drug Code (NDC) on every J2210 claim line, and some commercial payers have adopted the same rule. The NDC follows the 5-4-2 format (labeler-product-package). It goes in the claim’s drug identification loop, which is Loop 2410 on the 837P electronic claim, or as a narrative qualifier on paper claims.

The NDC qualifier for Medicaid submission is N4, placed immediately before the 11-digit NDC. The unit qualifier is UN (unit) or ML (milliliter), depending on the payer’s instructions. Confirm the format with each state Medicaid plan, because requirements vary. The NLM DailyMed database lists current NDCs for methylergonovine maleate injection products by manufacturer.

Medicare and Medicaid reimbursement for J2210

Medicare Part B reimburses J2210 using the Average Sales Price (ASP) methodology. The payment rate equals ASP plus 6% in a physician office setting. Dollar amounts change quarterly when CMS publishes updated ASP files. Check the current rate in the CMS Physician Fee Schedule lookup tool or the quarterly ASP pricing file before quoting a figure.

Hospital outpatient settings bill under the Outpatient Prospective Payment System (OPPS). OPPS rates differ from physician office rates because they include a facility component. A hospital-based outpatient department billing J2210 should use the OPPS Addendum B rate rather than the physician fee schedule allowable.

Medicaid coverage for J2210 varies by state. Most state plans cover methylergonovine maleate as a covered outpatient drug. Reimbursement rates, prior authorization thresholds, and NDC reporting rules still differ significantly. Review your state Medicaid agency’s drug fee schedule directly.

Prior authorization and medical necessity

Medicare Part B does not generally require prior authorization for J2210 when billed for covered postpartum hemorrhage indications. The drug falls within Part B’s coverage of injectable drugs administered incident-to a physician’s service.

Commercial payers vary. High-deductible plans and managed care organizations may require precertification for methylergonovine given electively or outside an acute hospital setting. For urgent postpartum hemorrhage cases, most commercial payers allow retrospective authorization. Document the clinical urgency in the medical record to support that request.

• Medicare Part B: No PA required for covered postpartum hemorrhage indications
• Medicaid: PA requirements vary by state plan, so check your state’s drug policy
• Commercial payers: PA may be required for non-urgent or off-label use, so confirm before administering in elective settings
• Medical necessity documentation: Diagnosis code (O72.x), vital signs indicating hemorrhage, drug order with route and dose, and provider credential

Codes commonly confused with J2210

Three codes turn up repeatedly in coder forums as mistaken substitutes for J2210. Each one is either a different drug or a deleted code that can no longer be submitted.

Documentation requirements for a J2210 claim

Strong J2210 documentation does two jobs. It establishes medical necessity, and it supports the billed unit count. Auditors look for consistency between the drug order, the administration note, and the units on the claim line. The medical record needs all of the following to pass a payer audit.

• ICD-10-CM diagnosis: O72.1 or O72.2 (or another covered postpartum hemorrhage code) on the claim, matching the chart
• Drug order: Signed order or authenticated verbal order specifying methylergonovine maleate, route, and dose in mg
• Dose administered: Nursing or physician note recording the mg given, time, and route (IM or IV)
• Discarded amount: Any drug wasted from the vial, which supports the JW line
• Lot number and expiry: Recorded for drug traceability and recall management
• NDC number: From the vial label, recorded in the administration note
• Provider credentials: Administering provider’s NPI and credential (MD, CNM, RN under physician supervision)
• Place of service: POS 11 (physician office), POS 21 (inpatient hospital), or POS 22 (outpatient hospital), which decides the fee schedule

Pabau, the practice management platform we build, ties drug administration records to claim lines in its claims management software. The biller sees the documented dose before entering the unit count.

Top reasons J2210 claims are denied and how to fix them

J2210 denials cluster around four root causes. They are missing modifiers, a wrong unit count, an absent NDC on Medicaid claims, and unsupported diagnosis codes. Each has a direct corrective path.

Recurring J2210 denials usually trace back to charge entry, where a missing modifier could have been flagged before the claim left the practice. Our guide to denial management covers how to route flagged remittances to the right person for correction.

How Pabau prevents J2210 claim denials

In many OB-GYN and women’s health practices, J2210 lines are still checked by hand. Someone reads the nursing note, converts mcg to mg, decides between JZ and a JW waste line, and copies the NDC from the vial.

Pabau moves those checks to the point of charge entry. Claims pass through its Claim.MD clearinghouse integration, which runs pre-submission edits against payer rules. A missing waste modifier or an absent NDC is flagged before the payer ever sees the claim.

The result is fewer returned Medicare claims and fewer Medicaid NDC denials. Your billers fix a modifier in minutes at submission instead of working an appeal weeks later.

Simplify J-code billing in your OB-GYN or women’s health practice

Pabau’s claims management software tracks HCPCS units, modifiers, and NDC fields in one workflow. Modifier and unit errors are caught before the claim leaves the practice.

Book a demo

Conclusion

J2210 denials rarely come from the drug itself. They come from three small decisions on the claim line, namely the unit count, the waste modifier, and the administration code.

Settle those decisions in the chart, not at the billing desk. When the note records the dose in mg, any discarded amount, the route, and the NDC, the biller is copying facts instead of guessing. Treat J2210 as a test of your wider medical billing workflow, because the same charting habits decide every single-dose vial you bill.

Book a demo to see how Pabau checks J2210 units, waste modifiers and NDCs before your OB-GYN claims go out.

Continue your research

Want to reduce claim rejections before they reach the payer? Clean claim best practices explains the pre-submission checks that cut denial rates across J-code billing.

Looking for guidance on electronic remittance and denial codes? Understanding electronic remittance advice (ERA) walks through how to read CARC and RARC codes from payer 835 files.

Choosing how your drug claims reach the payer? Medical claims clearinghouses explained covers how pre-submission edits catch modifier and NDC errors before a claim is filed.

Frequently asked questions